Singapore to Advance in cardiovascular research in next four years

Agilent Technologies and the National University of Singapore (NUS), through NUS Medicine, have teamed up to form a Center of Excellence in Cell Metabolism. The partnership is focused on progressing research in cardiovascular and metabolic disorders in singapore throughout the next four years.

Agilent's combined metabolic and cellular phenotyping systems like xCELLigence, Seahorse XF, and BioTek technologies streamline the process of studying cells. This will make it easier to find new targets for treatment and biomarkers for preventing cardiovascular, liver, and metabolic diseases.

Based on GlobalData's findings, NUS' Project RESET, focused on enhancing cardiovascular research in the country, is anticipated to benefit from increased global collaborations.

“By developing innovative, preventative healthcare strategies and enhancing local expertise in cardiovascular research, Singapore aims to reduce healthcare costs associated with CVDs. Furthermore, international collaborations will elevate Singapore’s status as a hub for biomedical research, attracting investment, talent, and boosting the local economy over time,” Shreya Jain, Medical Devices Analyst at GlobalData said.

The National University of Singapore (NUS) is a national public research university in Singapore. It was officially established in 1980 by the merger of the University of Singapore and Nanyang University. The university offers degree programmes in disciplines at both the undergraduate and postgraduate levels, including in the sciences, medicine and dentistry, design and environment, law, arts and social sciences, engineering, business, computing, and music.